BRPI0610209A2 - derivados espiro tricìclicos como moduladores de crth2 - Google Patents

derivados espiro tricìclicos como moduladores de crth2 Download PDF

Info

Publication number
BRPI0610209A2
BRPI0610209A2 BRPI0610209-3A BRPI0610209A BRPI0610209A2 BR PI0610209 A2 BRPI0610209 A2 BR PI0610209A2 BR PI0610209 A BRPI0610209 A BR PI0610209A BR PI0610209 A2 BRPI0610209 A2 BR PI0610209A2
Authority
BR
Brazil
Prior art keywords
chloro
pyrrolidin
indol
spiro
trioxo
Prior art date
Application number
BRPI0610209-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Matthias Schwarz
Eric Sebille
Cedric Merlot
Dennis Church
Jacqueline A Macritchie
John Frederick Atherall
Christophe Cleva
Patrick Page
Stefano Crosignani
Doris Pupowicz
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Publication of BRPI0610209A2 publication Critical patent/BRPI0610209A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0610209-3A 2005-05-24 2006-05-23 derivados espiro tricìclicos como moduladores de crth2 BRPI0610209A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05104428.7 2005-05-24
EP05104428 2005-05-24
US68863105P 2005-06-08 2005-06-08
US60/688,631 2005-06-08
PCT/EP2006/062545 WO2006125784A1 (en) 2005-05-24 2006-05-23 Tricyclic spiro derivatives as crth2 modulators

Publications (1)

Publication Number Publication Date
BRPI0610209A2 true BRPI0610209A2 (pt) 2010-06-01

Family

ID=35478408

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0610209-3A BRPI0610209A2 (pt) 2005-05-24 2006-05-23 derivados espiro tricìclicos como moduladores de crth2

Country Status (20)

Country Link
US (1) US8236963B2 (ja)
EP (1) EP1891075B1 (ja)
JP (1) JP5567268B2 (ja)
KR (1) KR101333861B1 (ja)
CN (1) CN101300259B (ja)
AR (1) AR055959A1 (ja)
AT (1) ATE529429T1 (ja)
AU (1) AU2006251138C1 (ja)
BR (1) BRPI0610209A2 (ja)
CA (1) CA2602965C (ja)
DK (1) DK1891075T3 (ja)
ES (1) ES2375614T3 (ja)
MX (1) MX2007014256A (ja)
NZ (1) NZ562772A (ja)
PL (1) PL1891075T3 (ja)
PT (1) PT1891075E (ja)
RU (1) RU2478639C2 (ja)
UA (1) UA90145C2 (ja)
WO (1) WO2006125784A1 (ja)
ZA (1) ZA200709819B (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ574705A (en) 2006-08-07 2011-12-22 Actelion Pharmaceuticals Ltd (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
US20120115895A1 (en) 2009-07-15 2012-05-10 Merck Serono S.A. Tricyclic indole-derived spiro derivatives as crth2 modulators
BR112012011317A2 (pt) 2009-11-12 2019-09-24 Univ Michigan Regents antagonistas espiro-oxindóis de mdm2
BR112012024114B1 (pt) 2010-03-22 2021-02-09 Idorsia Pharmaceuticals Ltd Compostos derivados de 3-(heteroarilamino)-1,2,3,4-tetrahidro-9h-carbazol, uso dos mesmos, e, composição farmacêutica
JP2014500870A (ja) 2010-11-12 2014-01-16 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン スピロ−オキシインドールｍｄｍ２アンタゴニスト
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
BR112013026283A8 (pt) 2011-04-14 2018-01-30 Actelion Pharmaceuticals Ltd derivados de ácido 7-(heteroaril-amino)-6,7,8,9-tetrahidropirido[1,2-a]indol acético e seu uso como moduladores do receptor d2 de prostaglandina
JP2014513699A (ja) 2011-05-11 2014-06-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン スピロ−オキシインドールｍｄｍ２アンタゴニスト
EP2790696A1 (en) 2011-12-16 2014-10-22 Atopix Therapeutics Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
CN103554119B (zh) * 2013-10-15 2015-09-16 华东师范大学 四氢呋喃并苯并二氢吡喃多环化合物的制备方法
CN103554118B (zh) * 2013-10-15 2015-08-19 华东师范大学 四氢呋喃并苯并二氢吡喃多环化合物及其应用
CN103554120B (zh) * 2013-10-16 2015-06-24 华东师范大学 3,3-螺(2-四氢呋喃)氧化吲哚多环状化合物的制备方法
CN103554121B (zh) * 2013-10-16 2015-06-24 华东师范大学 3,3-螺(2-四氢呋喃)氧化吲哚多环状化合物及其应用
SI3119779T1 (sl) 2014-03-17 2018-10-30 Idorsia Pharmaceuticals Ltd Derivati azaindolocetne kisline in njihova uporaba kot modulatorji prostaglandinskega receptorja D2
AU2015233046A1 (en) 2014-03-18 2016-11-03 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
KR20170124602A (ko) 2015-03-13 2017-11-10 포르마 세라퓨틱스 인크. Hdac8 억제제로서의 알파-신나미드 화합물 및 조성물
LT3322701T (lt) 2015-07-15 2019-07-10 F. Hoffmann-La Roche Ag Etinilo dariniai kaip metabotropinių glutamato receptorių moduliatoriai
WO2017046125A1 (en) 2015-09-15 2017-03-23 Actelion Pharmaceuticals Ltd Crystalline forms
RU2631856C1 (ru) * 2016-05-04 2017-09-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Чувашский государственный университет имени И.Н. Ульянова" Способ получения аммонийных солей 3-амино-8-гидрокси-1,6-диоксо-4-циано-2,7-диазаспиро[4.4]нон-3-ен-2-идов
DK3484889T3 (da) 2016-07-18 2020-10-26 Hoffmann La Roche Ethynylderivater
CN109369658B (zh) * 2017-08-08 2020-01-31 沈阳药科大学 一种螺[吡咯烷-3,3`-氧化吲哚]环系的合成方法
CN109384794B (zh) * 2017-08-08 2020-06-19 沈阳药科大学 质子酸催化的一类四环吲哚骨架的合成方法
CN109384787B (zh) * 2017-08-08 2021-04-16 沈阳药科大学 一种一价银催化的氢化吡啶螺二氢吲哚环的合成方法
KR101857408B1 (ko) 2018-02-28 2018-05-14 경북대학교 산학협력단 탈모 예방 또는 치료용 조성물
CN112876488B (zh) * 2021-02-18 2021-12-21 苏州大学 螺环吲哚啉衍生物及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE53102B1 (en) * 1981-05-12 1988-06-22 Ici Plc Pharmaceutical spiro-succinimide derivatives
IE52879B1 (en) * 1981-05-12 1988-03-30 Ici Plc Pharmaceutical spiro-hydantoin derivatives
US5948807A (en) * 1997-09-03 1999-09-07 Regents Of The University Of Minnesota Spiroindanamines and Spiroindanimides
DE60014603T2 (de) * 1999-03-12 2006-02-16 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel
SE0200411D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200356D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
GB2388540A (en) 2002-05-17 2003-11-19 Bayer Ag New use of Ramatroban
MXPA05003456A (es) 2002-10-04 2005-07-05 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
JP2006511486A (ja) 2002-10-21 2006-04-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｃｒｔｈ２拮抗剤としてのテトラヒドロキノリン誘導体
EP1471057B1 (en) 2003-04-25 2006-01-18 Actimis Pharmaceuticals, Inc. Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
WO2005007094A2 (en) 2003-07-09 2005-01-27 Tularik Inc. Asthma and allergic inflammation modulators
EP1740179A1 (en) 2004-04-20 2007-01-10 Pfizer Limited Method of treating neuropathic pain using a crth2 receptor antagonist

Also Published As

Publication number Publication date
RU2478639C2 (ru) 2013-04-10
EP1891075B1 (en) 2011-10-19
AU2006251138A1 (en) 2006-11-30
CA2602965A1 (en) 2006-11-30
CA2602965C (en) 2013-12-31
UA90145C2 (ru) 2010-04-12
PT1891075E (pt) 2011-11-10
EP1891075A1 (en) 2008-02-27
DK1891075T3 (da) 2011-12-19
ATE529429T1 (de) 2011-11-15
AU2006251138C1 (en) 2013-08-29
WO2006125784A1 (en) 2006-11-30
ES2375614T3 (es) 2012-03-02
CN101300259B (zh) 2013-08-28
PL1891075T3 (pl) 2011-12-30
CN101300259A (zh) 2008-11-05
US8236963B2 (en) 2012-08-07
US20090318486A1 (en) 2009-12-24
NZ562772A (en) 2010-01-29
KR101333861B1 (ko) 2013-11-28
JP2008542238A (ja) 2008-11-27
ZA200709819B (en) 2009-09-30
KR20080031191A (ko) 2008-04-08
RU2007147430A (ru) 2009-06-27
MX2007014256A (es) 2008-03-26
AR055959A1 (es) 2007-09-12
AU2006251138B2 (en) 2012-08-09
JP5567268B2 (ja) 2014-08-06

Similar Documents

Publication Publication Date Title
BRPI0610209A2 (pt) derivados espiro tricìclicos como moduladores de crth2
EP2035376B1 (en) Indoline amide derivatives as ep4 receptor ligands
KR101402557B1 (ko) 스피로-옥스인돌 화합물 및 이들의 치료제로서의 용도
JPH11512723A (ja) フィブリノゲン依存血小板凝集抑制物質としてのスピロ化合物
NZ286460A (en) N-(indole-2-carbonyl)aminoacid derivatives, n-(2-aminoacyl)azacyclic intermediates and pharmaceutical compositions
WO2008104055A1 (en) Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists
ES2260958T3 (es) Ligandos selectivos del receptor 5 - ht 6.
MX2007008277A (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d2.
KR20080073364A (ko) 인돌-3-일-카본일-스피로-피페리딘 유도체
TW202014185A (zh) 作為類視色素相關孤兒受體γ(RORγ)調節劑之苯并咪唑衍生物及其醫藥用途
BR112021002091A2 (pt) inibidores de indol e azaindol de enzimas pad
WO2015139619A1 (zh) 作为RORγ调节剂的化合物
CN110317202A (zh) 氰基吡咯并杂芳基类衍生物、其制备方法及其在医药上的应用
AU2020245614B2 (en) Serotonin 5-HT2B inhibitory compounds
TW202329941A (zh) Ｐａｄ４抑制劑及其用途

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MERCK SERONO S.A. (CH)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2412 DE 28-03-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.